Clinical Trials
80 trialsNCT02133196 2026-06-05
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03303495 2026-06-05
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Phase 3 Recruiting
NCT03841617 2026-06-05
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04585958 2026-06-05
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT04927416 2026-06-05
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05232409 2026-06-05
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Valley Health System
Phase 1 Recruiting
NCT05304858 2026-06-05
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
Columbia University
Recruiting
NCT06989437 2026-06-05
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
NCT07007559 2026-06-05
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07028125 2026-06-05
CANIQOL
Centre Francois Baclesse
Phase 4 Recruiting
NCT07629960 2026-06-05
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
Phase 1/2 Recruiting
NCT04621435 2026-06-04
Imaging of Solid Tumors Using FAP-2286
University of California, San Francisco
Phase 1 Recruiting
NCT05004116 2026-06-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT07174336 2026-06-04
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07222566 2026-06-04
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Phase 3 Recruiting
NCT07222800 2026-06-04
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT07227415 2026-06-04
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT07403721 2026-06-04
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
Phase 1 Recruiting
NCT07562152 2026-06-04
MAPKeeper 301
Immuneering Corporation
Phase 3 Recruiting
NCT07587216 2026-06-04
Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
Tongji Hospital
Recruiting
NCT07627711 2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2 Recruiting
NCT05023772 2026-06-03
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Henry Ford Health System
Phase NA Recruiting
NCT06040541 2026-06-03
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Recruiting
NCT06119581 2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT07086768 2026-06-03
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT07114601 2026-06-03
OMNIRAY
Eli Lilly and Company
Phase 1 Recruiting
NCT07197671 2026-06-03
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
University of Wisconsin, Madison
Phase 1 Recruiting
NCT07218380 2026-06-03
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
NCT04617522 2026-06-02
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Gilead Sciences
Phase 1 Recruiting
NCT05419518 2026-06-02
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05564377 2026-06-02
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06369831 2026-06-02
HERMIA
Abscint NV/SA
Phase 2 Recruiting
NCT06917079 2026-06-02
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT07046923 2026-06-02
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT07213817 2026-06-01
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07213830 2026-06-01
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
Phase 1/2 Recruiting
NCT06863272 2026-05-29
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07284186 2026-05-29
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
Phase 1 Recruiting
NCT07336238 2026-05-29
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Phase 2 Recruiting
NCT07612891 2026-05-29
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2 Recruiting
NCT05533697 2026-05-28
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT07137416 2026-05-28
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07335497 2026-05-28
ASCEND
Crescent Biopharma, Inc.
Phase 1/2 Recruiting
NCT07404332 2026-05-28
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
University of Iowa
Phase 1 Recruiting
NCT07612176 2026-05-28
A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NEOK Bio, Inc.
Phase 1 Recruiting
NCT05384626 2026-05-27
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT06247995 2026-05-27
NeoB-Cap1
Novartis
Phase 1/2 Recruiting
NCT06311214 2026-05-27
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting